- Home
- ALVO
ALVO
Alvotech
as 10-30-2025 4:00pm EST
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.
| Founded: | 2013 | Country: | Luxembourg |
| Employees: | N/A | City: | N/A |
| Market Cap: | 2.5B | IPO Year: | N/A |
| Target Price: | $14.00 | AVG Volume (30 days): | 351.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.22 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.35 - $13.70 | Next Earning Date: | 11-12-2025 |
| Revenue: | $562,478,000 | Revenue Growth: | 82.19% |
| Revenue Growth (this year): | 34.94% | Revenue Growth (next year): | 39.55% |
Latest Alvotech News
ALVO Breaking Stock News: Dive into ALVO Ticker-Specific Updates for Smart Investing
Zacks
10 days ago
Strength Seen in Cartesian Therapeutics, Inc. (RNAC): Can Its 8.2% Jump Turn into More Strength?
Simply Wall St.
13 days ago
Could Regulatory Progress on AVT23 Expand Alvotech’s (ALVO) Edge in European Biosimilars?
Simply Wall St.
a month ago
A Fresh Look at Alvotech (NasdaqGM:ALVO) Valuation After Recent Stock Uptick
Simply Wall St.
a month ago
EMA Greenlights for Key Biosimilars Might Change the Case for Investing in Alvotech (ALVO)
Simply Wall St.
4 months ago
Exploring 3 High Growth Tech Stocks in the US Market
TipRanks
4 months ago
Alvotech, Kashiv, Advanz announce study of AVT23 met primary endpoint
MT Newswires
4 months ago
Sector Update: Health Care Stocks Steady Pre-Bell Thursday
MT Newswires
4 months ago
Alvotech's Lenders Lower Term Loan Interest Rate
Compare ALVO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALVO Alvotech - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.